Does the use of nonrecommended doses of DOACs increase the risk of death in patients with atrial fibrillation?
Prescribing nonrecommended doses of DOACs in patients with atrial fibrillation is associated with increased mortality, highlighting the importance of adhering to guideline-directed dosing.
In GARFIELD-AF, most patients received the recommended DOAC doses according to country-specific guidelines. Prescription of nonrecommended doses was associated with an increased risk of death, mostly cardiovascular death, compared with patients on recommended doses, after adjusting for baseline factors. (Global Anticoagulant Registry in the Field-AF GARFIELD-AF; NCT01090362).
Camm et al. (Tue,) studied this question.